Recombinant staphylokinase variants with altered immunoreactivity. III: Species variability of antibody binding patterns.
BACKGROUND
The "charged cluster-to-alanine" substitution variants SakSTAR(K35A,E38A,K74A,E75A,R77A) and SakSTAR(K74A,E75A,R77A,E80A,D82A), previously identified as SakSTAR.M38 and SakSTAR.M89, respectively, induce less antibody formation in patients than wild-type recombinant staphylokinase (SakSTAR), but their specific activities are reduced by 50%. Therefore, the effect of the reversal of one or more of these substituted amino acids on the ratio of activity to antigenicity was studied.


RESULTS
Fourteen mutants with one to four "alanine-to-wild-type" reversals were expressed in Escherichia coli and highly purified (> 95%). In rabbits immunized with wild-type SakSTAR, the combined K35,E38,K74,E75,R77 or K74,E75,R77,E80,E82 epitope accounted for only 30% of antibody absorption from plasma, and no clear immunodominant residue could be identified. In baboons immunized with SakSTAR, the K35,E38 and K74,E75,R77 epitopes or the K74,E75,R77 and E80,D82 epitopes contributed equally to account for 50% of total antibody binding, but no immunodominant residues were apparent. In pooled plasma from patients with peripheral arterial occlusion treated with wild-type SakSTAR, about 40% of the antibodies depended on K74 of epitope K74,E75,R77 for binding, whereas epitopes K35,E38 and E80,D82 had a negligible contribution toward antibody recognition.


CONCLUSIONS
The recognition pattern by SakSTAR variants of antibodies induced with wild-type SakSTAR differs markedly among species. This implies that a systematic evaluation of reduced antigen recognition and antibody induction in humans will require the development of human or humanized systems. Surprisingly, SakSTAR(K74), with a single substitution of Lys74 with Ala, had an intact specific activity but did not absorb 40% of the antibodies induced in patients by treatment with wild-type SakSTAR.
Collen
D
D
Center for Molecular and Vascular Biology, University of Leuven, Belgium. desire.collen@med.kuleuven.ac.be
De Cock
F
F
Demarsin
E
E
Jenné
S
S
Lasters
I
I
Laroche
Y
Y
Warmerdam
P
P
Jespers
L
L
D000818:Animals; D000906:Antibodies / Q000276:immunology*; D000911:Antibodies, Monoclonal / Q000276:immunology; D001769:Blood / Q000187:drug effects; D006224:Cricetinae; D000939:Epitopes; D005343:Fibrinolytic Agents / Q000276:immunology* / Q000494:pharmacology; D014644:Genetic Variation; D006801:Humans; D007267:Injections; D008666:Metalloendopeptidases / Q000235:genetics* / Q000276:immunology* / Q000494:pharmacology; D051379:Mice; D009203:Myocardial Infarction / Q000097:blood; D010215:Papio; D011817:Rabbits; D011994:Recombinant Proteins; D013045:Species Specificity
D000906:Antibodies; D000911:Antibodies, Monoclonal; D000939:Epitopes; D005343:Fibrinolytic Agents; D011994:Recombinant Proteins; D008666:Metalloendopeptidases; C022653:auR protein, Staphylococcus aureus